SG55163A1 - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations

Info

Publication number
SG55163A1
SG55163A1 SG1996008480A SG1996008480A SG55163A1 SG 55163 A1 SG55163 A1 SG 55163A1 SG 1996008480 A SG1996008480 A SG 1996008480A SG 1996008480 A SG1996008480 A SG 1996008480A SG 55163 A1 SG55163 A1 SG 55163A1
Authority
SG
Singapore
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
SG1996008480A
Other languages
English (en)
Inventor
Juan Dedios Romero
Luis Carvajal Martin
Original Assignee
Beecham Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Lab Sa filed Critical Beecham Lab Sa
Publication of SG55163A1 publication Critical patent/SG55163A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG1996008480A 1991-05-08 1992-05-02 Pharmaceutical formulations SG55163A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919109862A GB9109862D0 (en) 1991-05-08 1991-05-08 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
SG55163A1 true SG55163A1 (en) 1998-12-21

Family

ID=10694582

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996008480A SG55163A1 (en) 1991-05-08 1992-05-02 Pharmaceutical formulations

Country Status (33)

Country Link
US (3) US6110497A (fr)
EP (3) EP0787487B1 (fr)
JP (1) JPH06507396A (fr)
KR (1) KR100228450B1 (fr)
CN (2) CN1056277C (fr)
AP (1) AP328A (fr)
AT (3) ATE285227T1 (fr)
AU (1) AU659836B2 (fr)
BR (1) BR9205948A (fr)
CA (1) CA2102630C (fr)
CZ (1) CZ291795B6 (fr)
DE (3) DE69233239T2 (fr)
DK (1) DK0585252T3 (fr)
ES (3) ES2235210T3 (fr)
FI (1) FI110354B (fr)
GB (1) GB9109862D0 (fr)
GR (1) GR3036937T3 (fr)
HU (1) HU219348B (fr)
IE (1) IE921472A1 (fr)
IL (1) IL101795A (fr)
MA (1) MA22522A1 (fr)
MX (1) MX9202118A (fr)
MY (1) MY111879A (fr)
NO (1) NO312224B1 (fr)
NZ (1) NZ242625A (fr)
PT (1) PT100458B (fr)
SA (1) SA92130069B1 (fr)
SG (1) SG55163A1 (fr)
SK (1) SK282333B6 (fr)
TW (1) TW240172B (fr)
WO (1) WO1992019227A2 (fr)
YU (1) YU49069B (fr)
ZA (1) ZA923272B (fr)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
GB9416599D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
EP0843552A2 (fr) * 1995-08-12 1998-05-27 Smithkline Beecham Plc Preparations pharmaceutiques
CZ299595B6 (cs) 1995-09-07 2008-09-17 Smithkline Beecham Plc Farmaceutický prípravek a lécivo pro empirickou lécbu infekcí
ATE216887T1 (de) * 1996-02-29 2002-05-15 Fujisawa Pharmaceutical Co Beta-lactam-antibiotikum enthaltende tabletten und verfahren zu deren herstellung
AT407701B (de) * 1996-08-12 2001-05-25 Biochemie Gmbh Zur direkttablettierung geeignete mischung, die als wesentliche komponenten amoxicillin-trihydrat und das kaliumsalz der clavulansäure enthält und verfahren zur herstellung dieser mischung
TWI225402B (en) * 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
US6893664B1 (en) 1996-06-17 2005-05-17 Powderject Research Limited Particle delivery techniques
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
GB9616536D0 (en) 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
AU6496498A (en) * 1997-02-07 1998-08-26 Gist-Brocades B.V. Homogeneous granulated formulations for dose sipping technology
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
CN1194687C (zh) * 1997-02-14 2005-03-30 史密斯克莱恩比彻姆药物实验室 含有阿莫西林和克拉维酸盐的药物制剂
EP1023065A1 (fr) * 1997-08-29 2000-08-02 Dsm N.V. Granules exempts d'excipients
DE19820801A1 (de) * 1998-05-09 1999-11-25 Gruenenthal Gmbh Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
US6177421B1 (en) 1999-05-04 2001-01-23 Fuisz International Ltd. Amoxicillin and clavulanate composition
WO2000025751A2 (fr) * 1998-10-30 2000-05-11 Fuisz International Ltd. Composition d'amoxycilline et de clavulanate amelioree
IE990159A1 (en) * 1999-02-26 2000-09-20 Fuisz Internat Ltd Storage Stable Amoxycillin and Clavulanate Suspension Composition.
SI1165049T2 (sl) 1999-04-01 2011-11-30 Dsm Ip Assets Bv Aglomerati s kristalizacijo
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
PE20010053A1 (es) * 1999-04-13 2001-03-10 Beecham Pharm Pte Ltd Formulacion de amoxicilina y clavulanato de potasio
US20020006433A1 (en) * 1999-04-29 2002-01-17 Nigel P. Davidson Pharmaceutical formulations
GB9930578D0 (en) * 1999-12-23 2000-02-16 Smithkline Beecham Plc Pharmaceutical formulations
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
WO2002030392A2 (fr) 2000-10-12 2002-04-18 Beecham Pharmaceuticals (Pte) Limited Nouvelle formulation
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
WO2002032906A1 (fr) * 2000-10-20 2002-04-25 Biochemie Gesellschaft M.B.H. Compositions pharmaceutiques
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US6720000B2 (en) 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
AT413983B (de) * 2001-04-12 2006-08-15 Sandoz Ag K-clavulanat in der form eines granulates
AT412344B (de) * 2001-04-12 2005-01-25 Sandoz Ag Hydrophobisierte teilchen von k-clavulanat
WO2003086343A2 (fr) * 2002-04-05 2003-10-23 Cadila Healthcare Limited Formes dosifiees orales se desintegrant rapidement
KR20050062514A (ko) * 2002-07-16 2005-06-23 랜박시 래보러터리스 리미티드 경구 투여용 분산성 정제
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7538094B2 (en) 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
CA2406592C (fr) * 2002-10-04 2003-09-30 Duchesnay Inc. Mode de preparation de formes posologiques pharmaceutiques contenant de multiples principes actifs
CA2533292C (fr) * 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Produit antibiotique, utilisation et formulation correspondantes
AU2004258944B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2533178C (fr) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Produit antibiotique, son utilisation et sa formulation
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
AU2004264939A1 (en) 2003-08-11 2005-02-24 Middlebrook Pharmaceuticals, Inc. Robust pellet
AU2004264356B2 (en) * 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005021056A1 (fr) * 2003-08-21 2005-03-10 Cns, Inc. Systeme de distribution de materiau effervescent
US8246996B2 (en) * 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
AU2004273830B2 (en) * 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005044236A1 (fr) * 2003-10-27 2005-05-19 Control Delivery Systems, Inc. Systeme d'administration en suspension pour une liberation localisee prolongee et controlee de produits pharmaceutiques
EP1701705A4 (fr) * 2003-12-24 2007-08-08 Advancis Pharmaceutical Corp Absorption amelioree de formes de dosage a liberation modifiee
EP1720533B1 (fr) * 2004-02-24 2015-03-25 Sandoz Ag Ganules instantanes d'amoxicilline
WO2005115347A1 (fr) * 2004-05-31 2005-12-08 Sam-A Pharmaceuticals Co., Ltd. Comprime dispersible comprenant des antibiotiques beta-lactame et procede de preparation dudit comprime
JP2008505124A (ja) * 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
ES2346147T3 (es) 2005-03-03 2010-10-11 Janssen Pharmaceutica Nv Derivados de oxa-diaza-espiro-(5.5)-undecanona sustituidos y su uso como antagonistas de las neuroquininas.
DE602006016244D1 (de) 2005-03-08 2010-09-30 Janssen Pharmaceutica Nv Diazaspiro-ä4,4ü-nonanderivate als neurokinin-(nk1)-antagonisten
WO2007058397A1 (fr) * 2005-11-17 2007-05-24 Gl Pharmtech Corp. Comprime dispersible comportant le melange d'amoxicilline et d'acide clavulanique ou ses sels et son procede de preparation
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
CA2810295C (fr) 2006-05-04 2017-11-14 Boehringer Ingelheim International Gmbh Une forme polymere de 1-((4-methyle-quinazoline-2-yl)methyle)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
CA2563690C (fr) * 2006-10-12 2014-10-07 Pharmascience Inc. Compositions pharmaceutiques comprenant des fractions intra- et extra- granulaires
FI20070521L (fi) 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
US8951562B2 (en) * 2006-11-10 2015-02-10 Atacama Labs Oy Method and apparatus or dry granulation
LT3150586T (lt) 2007-02-23 2020-03-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
JP2011500811A (ja) 2007-10-26 2011-01-06 レクサン ファーマシューティカルズ インコーポレイテッド クラブラン酸の医薬品製剤
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
CN102123700A (zh) 2008-05-02 2011-07-13 吉里德科学公司 固体载体颗粒在改善药物制剂加工性中的应用
WO2009135946A1 (fr) 2008-05-09 2009-11-12 Atacama Labs Oy Procédé et appareil de granulation par voie sèche
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TW201028168A (en) * 2008-12-19 2010-08-01 Solvay Pharm Bv Precompacted fast-disintegrating formulations of compounds with a low oral bioavailability
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
MY162494A (en) 2009-10-26 2017-06-15 Merck Sharp & Dohme Solid pharmaceutical compositions containing an integrase inhibitor
CA2782179C (fr) 2009-11-27 2020-06-23 Boehringer Ingelheim International Gmbh Traitement de patients diabetiques genotypes par des inhibiteurs de dpp-iv tels que la linagliptine
WO2011080502A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
EP2519229A2 (fr) 2009-12-29 2012-11-07 Novartis AG Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
EP2566464A1 (fr) * 2010-05-05 2013-03-13 Boehringer Ingelheim International GmbH Formulations pharmaceutiques comprenant de la pioglitazone et de la linagliptine
ES2953123T3 (es) 2010-06-24 2023-11-08 Boehringer Ingelheim Int Terapia para la diabetes
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2731947B1 (fr) 2011-07-15 2019-01-16 Boehringer Ingelheim International GmbH Quinazoline dimère substitué, sa préparation et son utilisation dans des compositions pharmaceutiques pour le traitement de la diabète type i et type ii
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (fr) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin pour son utilisation dans le traitement de l'albuminurie et des maladies liees au rein
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
EP2882423A1 (fr) * 2012-08-07 2015-06-17 Sandoz AG Comprimé non enrobé comprenant des granulés renfermant un antibiotique de type -lactame et du dioxyde de silicium hautement dispersé
JP2014079286A (ja) * 2012-10-12 2014-05-08 Hiroaki Koga 抗菌剤入容器
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
PL3518924T3 (pl) 2016-09-30 2023-01-09 Salix Pharmaceuticals, Inc. Postacie stałej dyspersji ryfaksyminy
HRP20240118T1 (hr) * 2016-10-24 2024-04-12 Janssen Sciences Ireland Unlimited Company Disperzivni pripravci

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1552416A (en) * 1975-08-12 1979-09-12 Beecham Group Ltd Pharmaceutical compositions
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
DE3134591A1 (de) * 1981-09-01 1983-03-10 Bayer Ag, 5090 Leverkusen Neue arzneimittelpraeparationen fuer glykosidhydrolasen-inhibitoren
ES2061623T3 (es) * 1987-03-02 1994-12-16 Brocades Pharma Bv Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
US5275823A (en) * 1989-04-27 1994-01-04 Smith Kline & French Laboratories Ltd. Pharmaceutical compositions
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
US5861172A (en) * 1991-05-08 1999-01-19 Laboratorios Beecham Sa Pharmaceutical formulations of compacted granulates of β-lactam antibiotics

Also Published As

Publication number Publication date
AP9200382A0 (en) 1992-07-31
EP0585252B1 (fr) 2001-07-25
CN1056277C (zh) 2000-09-13
NO312224B1 (no) 2002-04-15
WO1992019227A3 (fr) 1992-12-23
SA92130069B1 (ar) 2005-04-16
MX9202118A (es) 1993-03-01
CA2102630C (fr) 2004-01-13
WO1992019227A2 (fr) 1992-11-12
NO934009L (no) 1993-11-05
DE69233464D1 (de) 2005-01-27
AU659836B2 (en) 1995-06-01
SK112793A3 (en) 1994-06-08
JPH06507396A (ja) 1994-08-25
HU9303143D0 (en) 1994-01-28
DE69233239D1 (de) 2003-12-04
DE69231965D1 (de) 2001-08-30
YU47892A (sh) 1994-12-28
EP0783889A1 (fr) 1997-07-16
AP328A (en) 1994-03-23
ES2212034T3 (es) 2004-07-16
ES2161690T3 (es) 2001-12-16
HU219348B (en) 2001-03-28
PT100458B (pt) 1999-07-30
DE69233464T2 (de) 2006-04-13
MA22522A1 (fr) 1992-12-31
MY111879A (en) 2001-02-28
FI110354B (fi) 2002-12-31
SK282333B6 (sk) 2002-01-07
ZA923272B (en) 1993-03-31
DE69231965T2 (de) 2002-04-04
US6544558B2 (en) 2003-04-08
CZ237993A3 (en) 1994-03-16
KR100228450B1 (ko) 1999-11-01
GR3036937T3 (en) 2002-01-31
FI934914A0 (fi) 1993-11-05
IL101795A0 (en) 1992-12-30
ATE252900T1 (de) 2003-11-15
FI934914A (fi) 1993-11-05
EP0783889B1 (fr) 2003-10-29
DK0585252T3 (da) 2001-11-12
CN1067577A (zh) 1993-01-06
CA2102630A1 (fr) 1992-11-09
BR9205948A (pt) 1994-11-08
US6352720B1 (en) 2002-03-05
DE69233239T2 (de) 2004-08-19
ATE203400T1 (de) 2001-08-15
NO934009D0 (no) 1993-11-05
GB9109862D0 (en) 1991-07-03
CN1265882A (zh) 2000-09-13
AU1649892A (en) 1992-12-21
US6110497A (en) 2000-08-29
EP0787487A1 (fr) 1997-08-06
PT100458A (pt) 1993-08-31
TW240172B (fr) 1995-02-11
ES2235210T3 (es) 2005-07-01
CZ291795B6 (cs) 2003-05-14
EP0585252A1 (fr) 1994-03-09
CN1155370C (zh) 2004-06-30
HUT67020A (en) 1995-01-30
EP0787487B1 (fr) 2004-12-22
YU49069B (sh) 2003-08-29
US20020064562A1 (en) 2002-05-30
NZ242625A (en) 1994-08-26
IL101795A (en) 1996-10-16
IE921472A1 (en) 1992-11-18
ATE285227T1 (de) 2005-01-15

Similar Documents

Publication Publication Date Title
ZA923272B (en) Pharmaceutical formulations
EP0504112A3 (en) Pharmaceutical aerosol formulations
IL102777A0 (en) Pharmaceutical combination formulation
GB9114950D0 (en) Pharmaceutical formulation
ZA921093B (en) Pharmaceutical formulations
AP9000236A0 (en) Pharmaceutical formulations
GB9201639D0 (en) Pharmaceutical formulations
GB9323399D0 (en) Pharmaceutical formulations
GB9311030D0 (en) Pharmaceutical formulations
GB9216061D0 (en) Pharmaceutical combination formulation
GB9111858D0 (en) Pharmaceutical formulations
ZA92618B (en) Pharmaceutical formulations
GB9125005D0 (en) Pharmaceutical formulations
GB9103444D0 (en) Pharmaceutical formulations
GB9124803D0 (en) Pharmaceutical formulations
GB9114621D0 (en) Pharmaceutical formulations
GB9014391D0 (en) Pharmaceutical formulations
GB9207989D0 (en) Pharmaceutical formulations
GB9204774D0 (en) Pharmaceutical formulations
GB9207338D0 (en) Pharmaceutical formulations
GB9221244D0 (en) Pharmaceutical formulations
GB9203212D0 (en) Pharmaceutical formulations
GB9217602D0 (en) Pharmaceutical formulations
GB9116467D0 (en) Pharmaceutical formulation
GB9121798D0 (en) Pharmaceutical formulation